GalNAc-T15 in gastric adenocarcinoma: Characterization according to tissue architecture and cellular location

Gastric cancer (GC) is the second most common cause of cancer-related deaths in the world. This study aims to investigate the differential tissue expression of ppGalNAc- T15 and to evaluate its possible association with clinical-pathological parameters and outcome of gastric adenocarcinoma patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Albuquerque, Mário S. de Souza, Filho, Antônio F. da Silva, Cordeiro, Marina Ferraz, de Souza, Maria de Fátima Deodato, Quirino, Michael W. L., Lima, Luiza R. Amorim, Pitta, Maira G. da Rocha, Martins, Mário R., Rêgo, Moacyr J. B. de Melo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Brief Repor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038116/
https://www.ncbi.nlm.nih.gov/pubmed/29943957
http://dx.doi.org/10.4081/ejh.2018.2931
Descripción
Sumario:Gastric cancer (GC) is the second most common cause of cancer-related deaths in the world. This study aims to investigate the differential tissue expression of ppGalNAc- T15 and to evaluate its possible association with clinical-pathological parameters and outcome of gastric adenocarcinoma patients. For these 70 patients were evaluated the expression by immunohistochemistry to ppGalNAc-T15. Our results showed that 33 (47.1%) patients were ppGalNAc-T15+ positive and 37 (52.9%) negative. Positive staining for ppGalNAc-T15 was significantly present in patients older than 60 years (P= 0.0306) and submitted to total gastrectomy (P=0.0087). Also, some results remained at the limit of significance as surgical standing (P = 0.0562) and histological grade (P=0.0549). Therefore, the ppGalNAc-T15 immunoreactivity can be useful to understand the prognosis of patients with gastric cancer.

Ejemplares similares